Affiliation:
1. The Royal Marsden NHS Foundation Trust London UK
2. The Institute of Cancer Research London UK
Abstract
There are a number of androgen receptor targeted therapies available for patients with prostate cancer. There is no evidence of superior efficacy between these available drugs, so choice is mainly guided by toxicity, ease of use, monitoring, comorbidities and patient preference, as well as access to treatment
Reference32 articles.
1. Cancer ResearchUK. Prostate Cancer Statistics (www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer; accessed 22 August 2023).
2. STUDIES ON PROSTATIC CANCER
3. Androgen deprivation therapy for prostate cancer;Pagliarulo V.;Adv Exp Med Biol,2018
4. Mechanisms of resistance in castration‐resistant prostate cancer (CRPC);Chandrasekar T;Transl Androl Urol,2015
5. Abiraterone and Increased Survival in Metastatic Prostate Cancer